ATLANTA, GA--(Marketwire - June 04, 2008) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that five abstracts, which describe both clinical and pre-clinical diabetes and cardiovascular data from studies of its novel drug candidate, AGI-1067, have been accepted for the American Diabetes Association's (ADA) 68th Scientific Sessions taking place at the Moscone Convention Center in San Francisco, Calif. from June 6-10, 2008.
